A5058547281- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Chronic Lymphocytic Leukemia Research
- MicroRNA in disease regulation
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Cell Adhesion Molecules Research
- RNA Interference and Gene Delivery
- RNA Research and Splicing
- Glycosylation and Glycoproteins Research
- Genomics and Chromatin Dynamics
Oslo University Hospital
2022-2023
Vestre Viken Hospital Trust
2021-2023
University of Oslo
2022-2023
HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of on endogenous microRNA (miRNA) expression levels are unclear. We report responsive HER2 + cell lines had higher number miRNAs with altered after trastuzumab and lapatinib compared poorly lines. To evaluate whether can sensitize cells treatment, we performed high-throughput screen 1626 miRNA mimics inhibitors in combination cells. identified eight sensitizing...
Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer forms, and we assessed the effect mechanism of action this miRNA HER2+ cancer.Expression levels two clinical datasets, TCGA METABRIC, were compared between tumor normal adjacent samples, across molecular subtypes HER2 status. The ability sensitize for with lapatinib, tucatinib...
Serglycin is a proteoglycan highly expressed by immune cells, in which its functions are linked to storage, secretion, transport, and protection of chemokines, proteases, histamine, growth factors, other bioactive molecules. In recent years, it has been demonstrated that serglycin also several cell types, such as endothelial muscle multiple types cancer cells. Here, we show expression upregulated transforming factor beta (TGF-β) induced epithelial-mesenchymal transition (EMT). Functional...
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was identify compounds that substantially affect viability in HER2+ cells response combinatorial We performed high-throughput drug screen 278 combination with trastuzumab and lapatinib using two cell lines (KPL4 SUM190PT). The most...
Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose fatty acid metabolism. The antiproliferative role LXRs has been studied a variety malignancies may represent therapeutic opportunity cancers lacking targeted therapies, such as triple‐negative breast cancer. In this study, we investigated impact LXR agonists alone combination with carboplatin preclinical models vitro experiments revealed dose‐dependent decrease tumor...